Mohamed Abdelbaky | Pharmaceutical Science | Best Researcher Award

Posted on by Shen Awards

Prof. Dr. Mohamed Abdelbaky | Pharmaceutical Science | Best Researcher Award

Professor-Biochemistry from Avalon Medical School, Curaçao

Dr. Mohamed Fakhry Mohamed Abdelbaky is a distinguished professor of biochemistry with a robust academic and research background spanning over two decades. He earned his PhD in Biochemistry from Glasgow Caledonian University, UK, in 2011, following his MSc and MB.B.Ch from Minya University, Egypt. Dr. Abdelbaky has held significant academic positions across various international institutions, including Avalon University School of Medicine in Curaçao, Texila American University in Guyana, and Al Maarefa University in Saudi Arabia. His roles have encompassed curriculum development, teaching, student evaluation, and administrative leadership. His research interests are diverse, focusing on molecular biology, cancer research, and pharmacological studies, with numerous publications in reputable journals. Dr. Abdelbaky’s commitment to education and research excellence is evident through his active participation in academic committees, mentorship, and continuous professional development. His contributions have significantly advanced the field of biochemistry, making him a valuable asset to the scientific community.

Professional Profile

Education

Dr. Abdelbaky’s educational journey reflects a strong foundation in medical and biochemical sciences. He obtained his Bachelor of Medicine and Surgery (MB.B.Ch) from the Faculty of Medicine, Minya University, Egypt, in 2000. Pursuing his passion for biochemistry, he completed his Master of Science (MSc) in Biochemistry at the same institution in 2006, where his thesis focused on the effects of plasma homocysteine on VEGF levels in platelets and neutrophils. To further enhance his expertise, he pursued a PhD in Biochemistry and Molecular Biology at Glasgow Caledonian University, UK, completing it in 2011. His doctoral research investigated the biological effects of the proto-oncoprotein EVI1 in normal and transformed fibroblasts. This comprehensive educational background has equipped Dr. Abdelbaky with the knowledge and skills necessary to excel in both academic and research settings, contributing significantly to the field of biochemistry.

Professional Experience

Dr. Abdelbaky’s professional career is marked by a series of progressive academic appointments and responsibilities. He began as a Teaching Assistant at Minya University, Egypt, where he was involved in designing and supervising laboratory experiments for medical students. His dedication led to his promotion to Assistant Lecturer and subsequently to Lecturer, where he continued to contribute to teaching and research activities. He expanded his international experience by serving as a Postgraduate Demonstrator at Glasgow Caledonian University, UK, where he supervised laboratory sessions and research projects for science students. Dr. Abdelbaky furthered his academic career as an Assistant Professor at Al Maarefa University in Saudi Arabia, teaching medical biochemistry and genetics to students of various health science programs. He later joined Texila American University in Guyana as an Associate Professor, where he was responsible for curriculum design and delivery of biochemistry and medical genetics courses. Currently, he holds the position of Professor at Avalon University School of Medicine in Curaçao, where he continues to contribute to curriculum development, teaching, and student mentorship. Throughout his career, Dr. Abdelbaky has demonstrated a commitment to academic excellence and leadership in biochemistry education.

Research Interests

Dr. Abdelbaky’s research interests are centered around molecular biology, cancer research, and pharmacological studies. He has a particular focus on understanding the molecular mechanisms underlying various diseases, including cancer and metabolic disorders. His research explores the roles of specific genes and proteins in disease progression and treatment responses. Dr. Abdelbaky is also interested in the development and evaluation of pharmacological agents for disease prevention and therapy. His work often involves investigating the effects of natural compounds and pharmaceuticals on cellular and molecular pathways. Through his research, Dr. Abdelbaky aims to contribute to the development of effective diagnostic and therapeutic strategies for complex diseases, ultimately improving patient outcomes.

Research Skills

Dr. Abdelbaky possesses a comprehensive set of research skills that enable him to conduct advanced studies in biochemistry and molecular biology. He is proficient in tissue culture techniques, allowing for the cultivation and maintenance of various cell lines for experimental purposes. His expertise includes the isolation of DNA, RNA, and proteins, essential for analyzing gene and protein expression. Dr. Abdelbaky is skilled in polymerase chain reaction (PCR) and reverse transcription PCR (RT-PCR), techniques crucial for amplifying and studying specific DNA and RNA sequences. He is experienced in gene knockdown methods, which are used to study gene function by reducing gene expression. Additionally, he is adept at performing agarose and polyacrylamide gel electrophoresis (PAGE) for the separation and analysis of nucleic acids and proteins. These technical skills are fundamental to his research endeavors, enabling him to investigate complex biological processes and contribute valuable insights to the field of biochemistry.

Awards and Honors

Throughout his career, Dr. Abdelbaky has received recognition for his contributions to biochemistry and medical education. He is a member of several prestigious professional societies, including the Academy of Medical Educators (AoME) in the UK, the Egyptian Medical Syndicate, and the Egyptian Society of Medical Biochemistry. His active participation in these organizations reflects his commitment to professional development and collaboration within the scientific community. Dr. Abdelbaky has also contributed to the peer-review process for scientific journals, demonstrating his expertise and dedication to maintaining high standards in research publication. His involvement in continuous medical education (CME) programs and attendance at international conferences further highlight his pursuit of knowledge and excellence in his field. These accolades and affiliations underscore Dr. Abdelbaky’s standing as a respected figure in biochemistry and medical education.

Conclusion

Dr. Mohamed Fakhry Mohamed Abdelbaky’s extensive academic background, international teaching experience, and robust research portfolio position him as a leading figure in the field of biochemistry. His dedication to education is evident through his curriculum development efforts, mentorship, and active participation in academic committees. His research contributions have advanced the understanding of molecular mechanisms in disease and informed the development of therapeutic strategies. Dr. Abdelbaky’s technical expertise and commitment to professional growth have earned him recognition within the scientific community. His multifaceted career reflects a blend of academic excellence, research innovation, and leadership, making him a valuable asset to any institution and a strong candidate for accolades such as the Best Researcher Award.

Publications Top Notes

  1. Title: Enhanced sensitivity to hydrogen peroxide-induced apoptosis in Evi1 transformed Rat1 fibroblasts due to repression of carbonic anhydrase III
    Authors: Roy P, Reavey E, Rayne M, Roy S, Abed El Baky M, Ishii Y, Bartholomew C
    Year: 2010

  2. Title: BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia
    Authors: Roy S, Jørgensen HG, Roy P, Abed El Baky M, Melo JV, Strathdee G, Holyoake TL, Bartholomew C
    Year: 2012

  3. Title: Potential impact of urocortin I on sperm count, motility and sex hormone profiles in normal adult rats
    Authors: Hany A. El Kattawy, Mahmoud A. Naga, Ahmed Shata, Mohamed A. Elbaky
    Year: 2016

  4. Title: PTEN/PI3K/VEGF signaling pathway involved in the protective effect of xanthine oxidase inhibitor febuxostat against endometrial hyperplasia in rats
    Authors: MZ Mohamed, MF Abed El Baky, OA Hassan, HH Mohammed, AM Abdel-Aziz
    Year: 2020

  5. Title: The relation between ACKR4 and CCR7 genes expression and breast cancer metastasis
    Authors: Mostafa M. Mohammed, Olfat Shaker, Maggie M. Ramzy, Shereen S. Gaber, Heba S. Kamel, Mohamed F. Abed EL Baky
    Year: 2021

  6. Title: Aprepitant exerts anti-fibrotic effect via inhibition of TGF-β/Smad3 pathway in bleomycin-induced pulmonary fibrosis in rats
    Authors: Mervat Z. Mohamed, Mohamed F. Abed El Baky, Merhan E. Ali, Heba M. Hafez
    Year: 2022

  7. Title: Mirabegron alleviates acetic acid-induced colitis in rats: role of adiponectin and GSTM1/GSH detoxification pathway
    Authors: Mervat Z. Mohamed, Mohamed F. Abed El Baky, Sahar A. Mokhemer, Heba M. Hafez
    Year: 2023

  8. Title: Cardioprotective effect of Ginger in a rat model of myocardial damage and its possible intervention in PERK-ATF4-CHOP-PUMA apoptotic pathway
    Authors: M. M. Mohammed, N. A. A. Osman, F. M. Moura, M. F. Abedelbaky
    Year: 2023

  9. Title: Vinpocetine alleviates valproic acid-induced hepatotoxicity and neurotoxicity through activation of cAMP and PI3K/AKT/CREB pathway in rats
    Authors: Heba M. Hafez, Mohamed F. Abed El Baky, Sahar A. Mokhemer, Salma M. Hassan, Mervat Z. Mohamed
    Year: Under submission (anticipated 2024 or 2025)

Sutha Devaraj | Pharmaceutical Science | Best Academic Researcher Award

Posted on by Shen Awards

Dr. Sutha Devaraj | Pharmaceutical Science | Best Academic Researcher Award

Deputy Dean from Perdana University, Malaysia 

Sutha Devaraj is a dedicated researcher and academician with expertise in pharmaceutical sciences, specializing in drug discovery and pharmacology. She earned her Ph.D. in Pharmaceutical Sciences from Universiti Sains Malaysia (USM) in 2018, where her research focused on the development of optimized methods for preparing bioactive fractions of Strobilanthes crispus (L.) Bremek. Her work involved the quantification of the plant’s marker compound, contributing to advancements in natural product-based drug discovery. Before completing her Ph.D., Sutha obtained a Master’s in Pharmacology from USM in 2012. Her master’s thesis focused on the hepatoprotective properties of Curcuma xanthorrhiza Rox, exploring its potential for liver protection through its bioactive compounds. She also holds a B.Sc. (Hons) in Biotechnology from AIMST University, Malaysia, where she graduated with a CGPA of 3.41. This academic foundation in biotechnology provided her with a strong understanding of molecular biology and biochemistry, essential for her later research in pharmacology and drug development. Throughout her career, Sutha has contributed significantly to the study of plant-based compounds with medicinal properties, and her work has enhanced the understanding of their therapeutic potential. Her academic journey has been marked by a consistent focus on integrating practical research with innovative approaches in pharmaceutical sciences.

Professional Profile

Education

Sutha Devaraj’s educational background is distinguished by her specialized studies in pharmaceutical sciences and pharmacology. She earned her Ph.D. in Pharmaceutical Sciences with a focus on Drug Discovery from Universiti Sains Malaysia (USM) in 2018. Her doctoral thesis, titled Development of an Optimized Method for the Preparation of Bioactive Fraction of Strobilanthes crispus (L.) Bremek and the Quantification of its Marker Compound, was instrumental in advancing research on bioactive compounds derived from natural sources. This work enhanced the understanding of the therapeutic potentials of Strobilanthes crispus, contributing to both pharmaceutical science and ethnomedicine. Before completing her Ph.D., Sutha obtained her Master of Science (M.Sc.) in Pharmacology from USM in 2012. Her research focused on the hepatoprotective and pharmacological properties of Curcuma xanthorrhiza Rox, and she published findings related to the effectiveness of its standardized ethanolic extract in protecting the liver, demonstrating her expertise in pharmacological testing and drug development. Sutha’s academic journey began with a Bachelor of Science (B.Sc.) in Biotechnology (Hons) from AIMST University in 2008, where she graduated with a CGPA of 3.41. This early foundation in biotechnology paved the way for her subsequent advanced studies in pharmacology and pharmaceutical sciences.

Professional Experience

Sutha Devaraj has accumulated significant experience in the field of pharmaceutical sciences and pharmacology. Throughout her career, she has worked with various academic and research institutions, where she has contributed to advancing the understanding of pharmacological mechanisms and drug discovery. As a researcher at Universiti Sains Malaysia (USM), Sutha has actively participated in projects focusing on the isolation and quantification of bioactive compounds from plants, which has led to important findings on their therapeutic potentials. She has collaborated with both local and international researchers to examine the pharmacological properties of natural products, a focus that has shaped her work in drug discovery. In addition to her research roles, Sutha has also contributed to teaching and mentoring undergraduate and postgraduate students. She has shared her expertise in pharmacology and biotechnology, helping shape the next generation of scientists. Through her work, Sutha has built a strong professional reputation, earning recognition for her in-depth understanding of drug development processes and her ability to implement novel methodologies in her research.

Research Skills

Sutha Devaraj possesses a wide array of research skills essential to her work in pharmaceutical sciences and pharmacology. Her proficiency in bioactive compound isolation and quantification has been demonstrated through her research on Strobilanthes crispus and Curcuma xanthorrhiza, both of which are significant to natural drug discovery. She is highly skilled in pharmacological testing, utilizing a range of in-vitro and in-vivo models to assess the therapeutic efficacy of plant-based extracts. In addition to her experimental capabilities, Sutha has expertise in analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry, which she has used to identify and quantify bioactive compounds in complex matrices. Her background in biotechnology provides her with a solid understanding of biochemical assays, including enzyme inhibition and receptor binding assays. Furthermore, Sutha has honed her skills in data analysis and interpretation, often using sophisticated statistical tools to evaluate research results. Her ability to combine these skills allows her to contribute to cutting-edge research in drug discovery, particularly in exploring new therapeutic agents derived from natural sources.

Research Interests

Sutha Devaraj’s research interests lie at the intersection of pharmacology, drug discovery, and natural products. She is particularly focused on the exploration of plant-based bioactive compounds and their potential applications in pharmaceutical development. Her Ph.D. research on Strobilanthes crispus exemplifies her dedication to the discovery of new therapeutic agents from natural resources. Sutha is passionate about investigating the hepatoprotective and anticancer properties of various plant species, particularly those indigenous to Southeast Asia. She is also interested in the mechanisms of action of these compounds, aiming to elucidate how they interact with biological systems to exert therapeutic effects. In addition to pharmacological studies, Sutha is keen on formulation development, specifically in optimizing methods for the preparation and stabilization of bioactive extracts. Her future research endeavors include furthering the development of natural-based drugs with fewer side effects compared to conventional synthetic drugs, contributing to a more sustainable and effective approach in pharmaceutical therapy.

Awards and Honors

Sutha Devaraj’s career has been marked by notable recognition for her academic and research contributions. She was awarded a PhD Fellowship by Universiti Sains Malaysia (USM), providing her with the opportunity to carry out high-impact research in the field of pharmaceutical sciences. Additionally, her M.Sc. research on Curcuma xanthorrhiza earned her accolades for its significance in hepatoprotective studies. Sutha’s ability to combine scientific rigor with practical applications has led to her work being published in well-respected, peer-reviewed journals. Her academic excellence and contributions to the field have earned her membership in several prestigious academic organizations and editorial positions in prominent journals related to pharmacology and drug development. Her work continues to be recognized by the academic community, highlighting her as an emerging leader in her field of expertise.

Conclusion

In conclusion, Sutha Devaraj is an accomplished researcher with a strong academic background and expertise in pharmacology and drug discovery. Her dedication to advancing natural product research has led to valuable contributions in the areas of bioactive compound isolation and pharmacological evaluation. Sutha’s research skills, which include advanced analytical techniques and experimental methodologies, equip her to make meaningful advances in the development of therapeutic agents. Her research interests reflect a deep commitment to exploring sustainable and effective natural-based drugs, particularly those with hepatoprotective and anticancer properties. With a growing reputation in the field, Sutha’s work continues to inspire innovation in the pharmaceutical sciences, and her achievements and contributions make her a prominent figure in the ongoing search for new, safer therapeutic options.

Publications Top Notes

1. Evaluation of the Antinociceptive Activity and Acute Oral Toxicity of Standardized Ethanolic Extract of the Rhizome of Curcuma xanthorrhiza Roxb

  • Authors: S. Devaraj, A.S. Esfahani, S. Ismail, S. Ramanathan, M.F. Yam

  • Journal: Molecules, 15(4), 2925–2934

  • Year: 2010

  • Citations: 97

2. Investigation of Antioxidant and Hepatoprotective Activity of Standardized Curcuma xanthorrhiza Rhizome in Carbon Tetrachloride‐Induced Hepatic Damaged Rats

  • Authors: S. Devaraj, S. Ismail, S. Ramanathan, M.F. Yam

  • Journal: The Scientific World Journal, 2014(1), 353128

  • Year: 2014

  • Citations: 75

3. Evaluation of the Hepatoprotective Activity of Standardized Ethanolic Extract of Curcuma xanthorrhiza Roxb

  • Authors: S. Devaraj, S. Ismail, S. Ramanathan, S. Marimuthu, Y.M. Fei

  • Journal: Journal of Medicinal Plants Research, 4(23), 2512–2517

  • Year: 2010

  • Citations: 53

4. Anti-Tumor Action, Clinical Biochemistry Profile and Phytochemical Constituents of a Pharmacologically Active Fraction of S. crispus in NMU-Induced Rat Model

  • Authors: N.S. Yaacob, H.M. Yankuzo, S. Devaraj, J.K.M. Wong, C.S. Lai

  • Journal: PLoS One, 10(5), e0126426

  • Year: 2015

  • Citations: 41

5. A Study on the Hepatoprotective Effect of Andrographis paniculata (Burm. F) Nees on Mice

  • Author: D. Sutha

  • Journal: Journal of Phytology, 2(11)

  • Year: 2010

  • Citations: 35

6. In Vivo Toxicological Investigations of Standardized Ethanolic Extract of Curcuma xanthorrhiza Roxb. Rhizome

  • Authors: S. Devaraj, S. Ismail, S. Ramanathan, M. FeiYam

  • Journal: Journal of Natural Products and Plant Resources, 3(1), 67–73

  • Year: 2013

  • Citations: 28

7. Explorations of CRISPR/Cas9 for Improving the Long-Term Efficacy of Universal CAR-T Cells in Tumor Immunotherapy

  • Authors: M. Naeem, A. Hazafa, N. Bano, R. Ali, M. Farooq, S.I. Abd Razak, T.Y. Lee, et al.

  • Journal: Life Sciences, 316, 121409

  • Year: 2023

  • Citations: 23

8. Phytochemical, Antioxidant, Antipyretic and Anti-inflammatory Activities of Aqueous-Methanolic Leaf Extract of Mangifera indica

  • Authors: Q.U. Ain, M.O. Iqbal, I.A. Khan, N. Bano, M. Naeem, M.I. Jamaludin, S. Devaraj

  • Journal: American Journal of Translational Research, 15(7), 4533

  • Year: 2023

  • Citations: 15

9. Pathogenetic Mechanisms of Liver-Associated Injuries, Management, and Current Challenges in COVID-19 Patients

  • Authors: M. Naeem, N. Bano, S. Manzoor, A. Ahmad, N. Munawar, S.I.A. Razak, T.Y. Lee, et al.

  • Journal: Biomolecules, 13(1), 99

  • Year: 2023

  • Citations: 10

10. Innovative Aspects and Applications of Single Cell Technology for Different Diseases

  • Authors: A. Ali, S. Manzoor, T. Ali, M. Asim, G. Muhammad, A. Ahmad, M.I. Jamaludin, et al.

  • Journal: American Journal of Cancer Research, 14(8), 4028

  • Year: 2024

  • Citations: 1

11. Understanding the Role of Pharmacology and Toxicology in the Research, Development, and Innovation Process by Analyzing the Drug Development Process

  • Authors: L. Waheed, I. Ur Rehman, S. Devaraj, F.H.G.Q. Al-Amier, P. Jativa, G. Naz, et al.

  • Journal: Journal of Pharmaceutical Negative Results, Vol. 14

  • Year: 2023

  • Citations: 1

Eman Zahran | Pharmaceutical Science | Best Academic Researcher Award

Posted on by Shen Awards

Assoc. Prof. Dr. Eman Zahran | Pharmaceutical Science | Best Academic Researcher Award

Associate Professor of Pharmacognosy from Deraya university, Egypt

Dr. Eman Maher Zahran is a distinguished academic and researcher in the field of pharmacognosy, currently serving as an Associate Professor at Deraya University’s Faculty of Pharmacy. With a career rooted in natural product research, her work spans the morphological study of medicinal plants to the biological activities of phytoconstituents. A Ph.D. graduate from Minia University, she has demonstrated unwavering commitment to academic excellence, scientific innovation, and student mentorship. Her research integrates traditional knowledge with advanced technologies such as metabolomic profiling, ESI-HR-MS analysis, and molecular docking. Dr. Zahran has authored over 25 impactful peer-reviewed articles and delivered talks at key international and national pharmaceutical conferences. In addition to her scholarly contributions, she is actively involved in student-centered initiatives, scientific committees, and governmental outreach programs. Her editorial and peer-review work across several international journals further amplifies her impact within the global scientific community. A strong advocate for female leadership in science, she completed the prestigious “The Woman Leads” program at Egypt’s National Training Academy. Dr. Zahran’s blend of academic excellence, innovative research, leadership in community engagement, and dedication to advancing pharmacognosy education positions her as a leading figure in Egypt’s pharmaceutical sciences landscape.

Professional Profile

Education

Dr. Eman Maher Zahran’s educational journey is deeply rooted in Minia University, where she pursued her undergraduate, master’s, and doctoral degrees in Pharmaceutical Sciences with a specialization in Pharmacognosy. She completed her B.Sc. in Pharmaceutical Sciences in 2006 with a cumulative grade of “Very Good.” Her keen interest in medicinal plants and natural product research led her to undertake pre-master courses in 2007, which served as the foundation for her M.Sc. that spanned from 2007 to 2013. Her master’s research involved the detailed phytochemical investigation of plant constituents and their pharmacological evaluation. From 2016 to 2020, she pursued her Ph.D. at the Faculty of Pharmacy, Minia University, where she delved into advanced areas such as metabolomics, molecular docking, and structure elucidation of phytoconstituents. Her doctoral work not only reflected technical expertise but also interdisciplinary collaboration. During this academic trajectory, she also completed specialized training programs and participated in scientific workshops that refined her methodological capabilities. The strength of her education lies in its comprehensive nature, encompassing foundational knowledge, research techniques, and a critical understanding of the pharmacological potential of natural compounds, all of which have laid the groundwork for her ongoing contributions to pharmaceutical research and academia.

Professional Experience

Dr. Zahran’s professional trajectory reflects a steady and strategic ascent through the academic ranks of pharmacognosy. She began her journey as a community pharmacist, transitioning into academia in 2008 as a postgraduate researcher and then as a teaching assistant. Between 2010 and 2012, she served as a grant teaching assistant for Clinical Pharmacy students. From 2016 to 2020, she was appointed Associate Lecturer at the Faculty of Pharmacy, Minia University. In 2020, she was promoted to Assistant Professor, where she continued to lead educational initiatives, mentor students, and develop curricula. As of March 2025, she holds the rank of Associate Professor at Deraya University. Dr. Zahran has also been deeply involved in co-curricular activities, supervising multiple student-led initiatives such as “Hayah,” a student entity focused on scientific and community outreach. She has contributed to post-graduate course development and served on Deraya’s Quality Assurance and Accreditation Unit. Her participation in national-level training programs like “The Woman Leads” demonstrates her leadership and civic engagement. With over 15 years of diverse experience spanning pharmacy practice, teaching, and research, Dr. Zahran has emerged as a dynamic academic professional, recognized for her commitment to excellence, innovation, and interdisciplinary collaboration.

Research Interests

Dr. Zahran’s research interests center on pharmacognosy and natural product chemistry, with a strong emphasis on isolating, identifying, and evaluating bioactive phytoconstituents derived from medicinal plants and marine algae. Her work integrates classical botanical techniques with cutting-edge technologies like ESI-HR-MS analysis and molecular docking. A unique aspect of her research involves the application of network pharmacology to uncover the multi-target mechanisms of natural compounds, especially in treating complex disorders like ADHD and osteoarthritis. Her contributions extend to investigating the wound healing, antifungal, antiplasmodial, and anti-inflammatory properties of various natural substances. Recently, she has delved into combining natural phytochemicals with stem cell therapies to enhance regenerative medicine applications. Additionally, Dr. Zahran’s studies examine the environmental and biochemical effects of phytoconstituents using in vitro, in vivo, and in silico models. This holistic and multidisciplinary approach allows her to bridge the gap between traditional herbal medicine and contemporary pharmacological science. Her interest in neuropsychiatric disorders also reflects a forward-thinking orientation, exploring novel therapeutic avenues. Through her robust pipeline of projects and publications, she continues to identify plant-based compounds with the potential to be developed into pharmaceutical agents, contributing significantly to both academic knowledge and practical healthcare innovation.

Research Skills

Dr. Eman Maher Zahran is equipped with an extensive set of research skills that make her a leading expert in pharmacognosy and natural product research. She is proficient in the morphological and micromorphological analysis of medicinal plants and marine algae, with deep expertise in isolation and structure elucidation techniques for phytochemicals. Her methodological proficiency spans thin-layer chromatography (TLC), high-performance liquid chromatography (HPLC), and advanced mass spectrometric techniques, including ESI-HR-MS. Furthermore, she demonstrates high competence in molecular docking, network pharmacology, and in silico ADME studies, which she integrates seamlessly into phytochemical investigations. Dr. Zahran is also skilled in conducting both in vitro and in vivo biological activity assessments, exploring pharmacodynamics and pharmacokinetics of bioactive compounds. Her research frequently employs interdisciplinary approaches, such as combining plant extracts with mesenchymal stem cells in regenerative medicine models. Additionally, she is adept in scientific writing and publishing, having authored numerous high-impact papers in Scopus-indexed and Web of Science journals. Her peer-review activities and editorial board membership further reflect her critical appraisal capabilities. Collectively, her skills not only underscore her technical competence but also her innovative spirit and dedication to producing translational research that advances healthcare through natural product pharmacology.

Awards and Honors

Dr. Eman Maher Zahran has garnered significant recognition for her academic achievements, both within her institution and the broader scientific community. She was honored by Deraya University for her outstanding academic contributions from 2020 onward, a period during which she published prolifically and advanced numerous research projects. Her active role in student development and community outreach, particularly through her supervision of the “Hayah” entity and ADHD-focused conferences, highlights her multifaceted impact. In 2023, she was selected to join the second cohort of the Egyptian National Training Academy’s “The Woman Leads” program, which is designed to empower and equip promising female leaders in science and education. She serves as an editorial board member and peer reviewer for multiple prestigious journals, including the Journal of Pharmaceutical Chemistry & Chemical Science, Octahedron Drug Research, and journals by the Royal Society of Chemistry. Furthermore, her selection to the scientific committee of international congresses on nanoscience and pharmacology reflects her expertise and respected standing in the academic community. These honors not only affirm her scientific merit but also her leadership, dedication to knowledge dissemination, and her influential role in shaping the future of pharmacognosy in Egypt and beyond.

Conclusion

Dr. Eman Maher Zahran exemplifies the qualities of a dedicated academic, an innovative researcher, and an inspiring mentor. Her career is marked by a relentless pursuit of excellence, from foundational studies in pharmaceutical sciences to cutting-edge research in natural product pharmacology. Her interdisciplinary focus—combining phytochemistry, molecular modeling, and regenerative medicine—demonstrates her commitment to translating traditional medicinal knowledge into therapeutic breakthroughs. Dr. Zahran’s engagement with students, leadership in research committees, and active role in scientific communication reflect her holistic academic persona. Her prolific publication record, participation in international conferences, and collaborations underscore her relevance on both national and global levels. Equally commendable is her devotion to community-based initiatives, particularly in raising awareness and support for neuropsychiatric conditions like ADHD. Her recognition through institutional awards and national leadership programs stands as a testament to her impact. As she continues to expand her research footprint and inspire the next generation of scientists, Dr. Zahran remains a vital force in the advancement of pharmacognosy and pharmaceutical sciences. Her contributions resonate far beyond the laboratory and classroom, positioning her as a role model and a key influencer in the evolving landscape of academic research and community health promotion.

Publications Top Notes

  • Title: Diversity, phytochemical and medicinal potential of the genus Ocimum L. (Lamiaceae)
    Authors: EM Zahran, UR Abdelmohsen, HE Khalil, SY Desoukey, MA Fouad, …
    Year: 2020
    Citations: 86

  • Title: Bioactivity potential of marine natural products from scleractinia-associated microbes and in silico anti-SARS-COV-2 evaluation
    Authors: EM Zahran, A Albohy, A Khalil, AH Ibrahim, HA Ahmed, EM El-Hossary, …
    Year: 2020
    Citations: 41

  • Title: Antioxidant and wound healing potential of Vitis vinifera seeds supported by phytochemical characterization and docking studies
    Authors: T Al-Warhi, EM Zahran, S Selim, MM Al-Sanea, MM Ghoneim, SA Maher, …
    Year: 2022
    Citations: 36

  • Title: Multitarget in silico studies of Ocimum menthiifolium, family Lamiaceae against SARS-CoV-2 supported by molecular dynamics simulation
    Authors: A Albohy, EM Zahran, UR Abdelmohsen, MA Salem, T Al-Warhi, …
    Year: 2022
    Citations: 29

  • Title: Antiulcer potential and molecular docking of flavonoids from Ocimum forskolei Benth., family Lamiaceae
    Authors: EM Zahran, UR Abdelmohsen, AS Hussein, MA Salem, HE Khalil, …
    Year: 2021
    Citations: 27

  • Title: Scabicidal potential of coconut seed extract in rabbits via downregulating inflammatory/immune cross talk: A comprehensive phytochemical/GC-MS and in silico proof
    Authors: EM Zahran, NMR Abdel-Maqsoud, OY Tammam, IM Abdel-Rahman, …
    Year: 2022
    Citations: 23

  • Title: New Acaciin-loaded self-assembled nanofibers as MPro inhibitors against BCV as a surrogate model for SARS-CoV-2
    Authors: SA Mohamad, EM Zahran, MR Abdel Fadeel, A Albohy, MA Safwat
    Year: 2021
    Citations: 23

  • Title: New halogenated compounds from Halimeda macroloba seaweed with potential inhibitory activity against malaria
    Authors: AH Elmaidomy, EM Zahran, R Soltane, A Alasiri, H Saber, CJ Ngwa, …
    Year: 2022
    Citations: 22

  • Title: Metabolic profiling, histopathological anti-ulcer study, molecular docking and molecular dynamics of ursolic acid isolated from Ocimum forskolei Benth. (family Lamiaceae)
    Authors: EM Zahran, UR Abdelmohsen, AT Ayoub, MA Salem, HE Khalil, …
    Year: 2020
    Citations: 21

  • Title: Cytotoxic and anti-diabetic potential, metabolic profiling and in silico studies of Syzygium cumini (L.) Skeels belonging to family Myrtaceae
    Authors: SS Eldin Elhawary, AE Elmotayam, D Alsayed, EM Zahran, MA Fouad, …
    Year: 2022
    Citations: 11

Haiyang Yu | Pharmaceutical Science | Best Researcher Award

Posted on by Shen Awards

Prof. Haiyang Yu | Pharmaceutical Science | Best Researcher Award

Professor at Tianjin University of Traditional Chinese Medicine, China

Professor Haiyang Yu is an accomplished researcher and academic in the field of pharmacology and traditional Chinese medicine. With a focus on the anti-tumor molecular mechanisms of natural products, he has significantly contributed to cancer research. His work delves into understanding how small molecules in traditional Chinese medicine and other natural sources can target cancerous cells. Throughout his career, Professor Yu has gained recognition for his work, publishing over 40 peer-reviewed articles, including in prestigious journals such as Nature Communications and the Journal of Hematology & Oncology. He has also led six national research projects. His lab at Tianjin University of Traditional Chinese Medicine explores the pharmacological potential of these compounds, using network pharmacology to identify new drug targets and elucidate the molecular mechanisms behind anti-tumor effects. His research has the potential to transform cancer treatment by merging the ancient wisdom of TCM with modern scientific methods.

Professional Profile

Education

Professor Haiyang Yu holds a Ph.D. from Dong-a University, where he honed his academic foundation in pharmacology and molecular biology. After earning his doctoral degree, he pursued postdoctoral research training from 2012 to 2014, furthering his expertise in the molecular mechanisms of disease and drug discovery. This rigorous academic journey provided him with the necessary skills to embark on significant research in cancer pharmacology. His educational background underscores his commitment to advancing scientific knowledge, particularly in integrating traditional medicine with modern pharmacological practices. Professor Yu’s academic credentials have shaped him into a leader in his field, allowing him to explore novel therapeutic pathways for cancer treatment through natural products and traditional Chinese medicine.

Professional Experience

Currently serving as a professor at Tianjin University of Traditional Chinese Medicine, Professor Haiyang Yu has built a distinguished career. His position allows him to influence the next generation of researchers while continuing his own innovative work. His research is primarily concerned with the anti-tumor effects of natural products, an area in which he has published extensively. He has presided over six national projects, demonstrating his leadership capabilities and ability to secure funding for significant research initiatives. Prior to this, Professor Yu gained invaluable postdoctoral experience, expanding his research scope and applying his findings in practical settings. His experience includes collaborations with international researchers, which further enhances his ability to contribute to the global understanding of cancer pharmacology. Throughout his career, Professor Yu has successfully blended traditional Chinese medicine and contemporary research techniques, achieving breakthroughs that have had an impact on both scientific and medical communities.

Research Interests

Professor Haiyang Yu’s research primarily focuses on network pharmacology, natural products, traditional Chinese medicine (TCM), and cancer drug discovery. His interest lies in uncovering the molecular mechanisms by which natural compounds, especially those derived from TCM, exhibit anti-cancer properties. By employing advanced techniques in network pharmacology, Professor Yu investigates how these compounds interact with specific drug targets to inhibit cancer cell growth. His lab’s research aims to explore novel drug targets that could lead to more effective cancer therapies. A key part of his research involves exploring the synergy between traditional Chinese medicine and modern pharmacological methods, bridging ancient knowledge with cutting-edge technology. This interdisciplinary approach is central to his work, providing new avenues for the development of cancer treatments and potentially improving the effectiveness of existing therapies.

Research Skills

Professor Haiyang Yu’s research skills encompass a broad array of advanced techniques in pharmacology, molecular biology, and bioinformatics. His expertise in network pharmacology enables him to explore the complex interactions between small molecules and drug targets, a crucial area for drug discovery. Additionally, his proficiency in cell biology and molecular biology techniques, such as cell culture, gene expression analysis, and protein assays, allows him to delve deep into the cellular mechanisms underlying cancer progression. Professor Yu’s lab also employs cutting-edge computational tools to predict drug-target interactions and evaluate the therapeutic potential of natural compounds. Furthermore, his extensive experience with bioinformatics allows for the integration of large-scale biological data, which is essential for identifying potential therapeutic pathways and developing novel cancer drugs. His skills in both experimental and computational research make him a leading figure in his field.

Awards and Honors

Professor Haiyang Yu has received numerous accolades for his groundbreaking contributions to cancer research and traditional Chinese medicine. He has been recognized for his leadership in national research projects, successfully leading six such initiatives that have received considerable funding. His outstanding scholarly work has earned him a reputation as a leading expert in his field, culminating in invitations to present at international conferences and contribute to high-impact journals. His publication record, which includes over 40 papers in prestigious journals such as Nature Communications and the Journal of Hematology & Oncology, underscores his standing within the scientific community. These honors not only reflect his individual achievements but also highlight his capacity to drive scientific innovation in pharmacology and oncology. Professor Yu’s ongoing contributions continue to shape the direction of research in cancer therapies and natural product pharmacology.

Conclusion

Professor Haiyang Yu is an exceptional candidate for recognition as a Best Researcher. With a solid educational background, extensive professional experience, and a significant body of research publications, he has established himself as a leader in the field of cancer research and traditional Chinese medicine. His work in identifying novel anti-tumor mechanisms through natural products and network pharmacology has the potential to revolutionize cancer therapy. His leadership in national research projects, combined with his innovative research methods, has led to significant advancements in the understanding of cancer and drug discovery. As an academic and researcher, Professor Yu continues to push the boundaries of pharmacology, integrating traditional wisdom with modern scientific methodologies. His achievements reflect both personal excellence and a broader commitment to the advancement of cancer research, making him a deserving candidate for the Best Researcher Award.

Publication Top Notes

  1. Title: Autocrine and paracrine LIF signals to collaborate sorafenib-resistance in hepatocellular carcinoma and effects of Kanglaite Injection
    Authors: Shao, Y., Pu, W., Su, R., Han, L., Yu, H.
    Year: 2025
  2. Title: Intestinal FXR deficiency induces dysregulation of xanthine oxidase and accounts for sex difference in hyperuricemia
    Authors: Bao, R., Chen, B., Wang, A., Zhang, Y., Wang, T.
    Year: 2025
  3. Title: Immunometabolism in cancer: basic mechanisms and new targeting strategy
    Authors: Su, R., Shao, Y., Huang, M., Yu, H., Qiu, Y.
    Year: 2024
    Citations: 4
  4. Title: Arnicolide D induces endoplasmic reticulum stress-mediated oncosis via ATF4 and CHOP in hepatocellular carcinoma cells
    Authors: Lin, Y.-S., Sun, Z., Shen, L.-S., Chen, S., Chen, G.-Q.
    Year: 2024
    Citations: 6
  5. Title: Babaodan inhibits cell proliferation and metastasis and enhances anti-tumor effects of camrelizumab by inhibiting M2 phenotype macrophages in hepatocellular carcinoma
    Authors: Liu, C., Lin, X., Huang, M., Qiu, Y., Yu, H.
    Year: 2024
    Citations: 2
  6. Title: Energy Landscape Reveals the Underlying Mechanism of Cancer-Adipose Conversion in Gene Network Models
    Authors: Chen, Z., Lu, J., Zhao, X.-M., Yu, H., Li, C.
    Year: 2024
  7. Title: Repurposing cyclovirobuxine D as a novel inhibitor of colorectal cancer progression via modulating the CCT3/YAP axis
    Authors: Liu, Y., Chen, L., Wang, J., Wang, T., Yu, H.
    Year: 2024
  8. Title: The role of NCAPH in cancer treatment
    Authors: Liu, C., Han, X., Zhang, S., Pu, W., Yu, H.
    Year: 2024
  9. Title: Dan-shen Yin promotes bile acid metabolism and excretion to prevent atherosclerosis via activating FXR/BSEP signaling pathway
    Authors: Sheng, Y., Meng, G., Zhang, M., Wang, Y., Jiang, M.
    Year: 2024
    Citations: 2
  10. Title: Natural products with anti-tumorigenesis potential targeting macrophage
    Authors: Liu, H., Huang, M., Xin, D., Yu, H., Pu, W.
    Year: 2024

 

Yanan Jiang | Pharmaceutical Science | Best Researcher Award

Posted on by Shen Awards

Prof. Yanan Jiang | Pharmaceutical Science | Best Researcher Award

Professor at Harbin Medical University, China

Dr. Yanan Jiang is a Professor at Harbin Medical University, where she has been actively contributing to the field of pharmacology through impactful research and academic leadership. Her work primarily focuses on understanding the mechanisms of arsenic trioxide, therapeutic targets for cardiac injury, and the bioinformatics analysis of tumor and cardiovascular disease targets. With a robust academic foundation and over 26 SCI-indexed publications as the first or corresponding author, Dr. Jiang has established herself as a multidisciplinary researcher. She has secured funding for eight research projects, including prestigious grants from the National Natural Science Foundation of China. Additionally, Dr. Jiang serves on the editorial board of Scientific Reports and as a guest editor for four SCI journals. Her career reflects a balance of research innovation, academic excellence, and leadership in the global scientific community.

Professional Profile

Education

Dr. Jiang holds a Ph.D. in Pharmacology from Harbin Medical University, which she completed in December 2016. Her doctoral research laid the foundation for her current focus on molecular mechanisms in pharmacology and bioinformatics. Prior to this, she earned a Bachelor of Science in Traditional Chinese Medicine from the same university in 2010. This dual educational background integrates modern pharmacological techniques with traditional Chinese medicinal principles, enabling her to adopt a unique and comprehensive approach in her research. Her academic credentials highlight a commitment to understanding and innovating within pharmacological sciences.

Professional Experience

Dr. Jiang began her academic career as a Lecturer at Harbin Medical University in 2017. She was later promoted to Associate Professor, a role she held from 2017 to 2023, during which she also pursued a postdoctoral fellowship focusing on bioinformatics. Her postdoctoral research enhanced her expertise in utilizing computational approaches to study tumor and cardiovascular disease mechanisms. In September 2023, Dr. Jiang was appointed Professor at Harbin Medical University, a position that underscores her leadership and research excellence. Over the years, she has played a pivotal role in advancing pharmacology and bioinformatics, reflecting her versatility and dedication to interdisciplinary research.

Research Interests

Dr. Jiang’s research interests center around pharmacology, particularly the mechanisms and therapeutic applications of arsenic trioxide. She investigates the molecular pathways of cardiac injury and explores potential therapeutic targets to mitigate its impact. Additionally, she applies bioinformatics to analyze tumor and cardiovascular disease mechanisms, identifying novel biomarkers and therapeutic targets. Her multidisciplinary approach bridges traditional pharmacology and cutting-edge computational techniques, enabling the development of innovative treatment strategies. Dr. Jiang’s research not only contributes to the fundamental understanding of disease mechanisms but also holds significant translational potential for clinical applications.

Research Skills

Dr. Jiang possesses a diverse skill set that includes molecular pharmacology, bioinformatics, and experimental design for preclinical studies. Her expertise extends to the computational analysis of large datasets to identify disease biomarkers and therapeutic targets. She is proficient in leading complex, multi-institutional research projects, as evidenced by her role as principal investigator for eight funded studies. Her ability to integrate experimental and computational methods enhances her capability to tackle multifaceted scientific questions. Furthermore, Dr. Jiang’s editorial experience with renowned journals equips her with advanced skills in peer review, scientific communication, and publication management.

Awards and Honors

Dr. Jiang has been the recipient of multiple prestigious awards and honors that reflect her academic and research excellence. She has been awarded competitive grants, including those from the National Natural Science Foundation of China and the China Postdoctoral Science Foundation, highlighting her ability to attract substantial research funding. Her editorial roles with Scientific Reports and other SCI-indexed journals underscore her recognition as a leading expert in her field. These accolades, combined with her promotion to Professor at a young age, illustrate her significant contributions to pharmacology and bioinformatics, positioning her as a distinguished researcher in the scientific community.

Conclusion

Dr. Yanan Jiang is a highly competitive candidate for the Best Researcher Award, given her strong academic trajectory, robust research output, and success in securing funding. Her multidisciplinary expertise in pharmacology and bioinformatics, combined with her leadership roles in journals, underlines her prominence in her field. To further solidify her candidacy, she could emphasize her international collaborations, citation metrics, and mentorship contributions. Nonetheless, her accomplishments and expertise align well with the criteria for this award, making her a worthy contender.

Publication Top Notes

  1. Intestinal microbiota homeostasis analysis in riboflavin-treated alcoholic liver disease
    Authors: Shen, X., Shi, C., Xu, J., … Jiang, Y., Sun, H.
    Year: 2024
  2. Comprehensive characterization of long QT syndrome-associated genes in cancer and development of a robust prognosis model
    Authors: Xu, J., Wen, Z., She, Y., … Wang, S., Jiang, Y.
    Year: 2024
  3. Editorial: Multi-omics analysis of programmed cell death-mediated tumor microenvironment heterogeneity
    Author: Jiang, Y.
    Year: 2024
  4. An overview of arsenic trioxide-involved combined treatment algorithms for leukemia: basic concepts and clinical implications
    Authors: Jiang, Y., Shen, X., Zhi, F., … Yang, B., Bai, Y.
    Year: 2023
    Citations: 15
  5. Correction: The involvement and therapeutic potential of lncRNA Kcnq1ot1/miR-34a-5p/Sirt1 pathway in arsenic trioxide-induced cardiotoxicity
    Authors: Shen, X., Zhi, F., Shi, C., … Bai, Y., Yang, B.
    Year: 2023
    Citations: 1
  6. The involvement and therapeutic potential of lncRNA Kcnq1ot1/miR-34a-5p/Sirt1 pathway in arsenic trioxide-induced cardiotoxicity
    Authors: Shen, X., Zhi, F., Shi, C., … Jiang, Y., Yang, B.
    Year: 2023
    Citations: 10
  7. Open a new epoch of arsenic trioxide investigation: ATOdb
    Authors: Jiang, Y., Li, J., Liu, Y., … Shao, T., Xu, Y.
    Year: 2023
  8. Characterization of the metabolic alteration-modulated tumor microenvironment mediated by TP53 mutation and hypoxia
    Authors: Luo, K., Qian, Z., Jiang, Y., … Jin, S., Shang, D.
    Year: 2023
    Citations: 16
  9. From Phenomenon to Essence: A Newly Involved lncRNA Kcnq1ot1 Protective Mechanism of Bone Marrow Mesenchymal Stromal Cells in Liver Cirrhosis
    Authors: Zhangdi, H., Jiang, Y., Gao, Y., … Geng, X., Jin, S.
    Year: 2023
    Citations: 2
  10. Research Progress of New Dosage Forms of Arsenic Trioxide | 三氧化二砷新剂型的研究进展
    Authors: Liao, R., Shi, C., Fu, W., … Zhi, F., Jiang, Y.
    Year: 2023
    Citations: 1